Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
510 participants
INTERVENTIONAL
2018-01-08
2028-06-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assess Cancer in Ovarian Tumors With Biomarkers.
NCT00436189
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692
Ovarian Tumor Biopsies to Study Response to Treatments
NCT02952521
New Biomarkers Evaluating Ovarian Cancer
NCT01466049
A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer
NCT06483425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sample Collection
The following samples may be collected during the study:
* Tumour tissue samples
* Blood samples
* Ascites samples
* Other fluids requiring drainage
Tumour tissue collection
Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:
* At the time of diagnosis or progression
* Any surgical procedures for management of tumour related medical conditions
* At each subsequent relapse or disease progression
Blood sample collection
Blood samples will be taken:
* At the time of first diagnosis
* About 1 week after starting any treatment
* At each radiological response assessment
* At each subsequent relapse or disease progression
Ascites Collection
Ascites will be collected if paracentesis is required during any of the following time points:
* At the time of diagnosis or progression
* Any surgical procedures for management of tumour related medical conditions
* At each subsequent relapse or disease progression
Fluid Collection
Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumour tissue collection
Tumour tissue will be taken from samples already removed from surgery or biopsy or by new tumour biopsies:
* At the time of diagnosis or progression
* Any surgical procedures for management of tumour related medical conditions
* At each subsequent relapse or disease progression
Blood sample collection
Blood samples will be taken:
* At the time of first diagnosis
* About 1 week after starting any treatment
* At each radiological response assessment
* At each subsequent relapse or disease progression
Ascites Collection
Ascites will be collected if paracentesis is required during any of the following time points:
* At the time of diagnosis or progression
* Any surgical procedures for management of tumour related medical conditions
* At each subsequent relapse or disease progression
Fluid Collection
Additional fluid will be collected at any time a procedure for clinical management that involves the drainage of fluid (i.e. thoracentesis, or drainage of cystic lesion) is required.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must be 18 years of age or older.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
* Have a life expectancy greater than or equal to 6 months.
* Able to provide adequate informed consent.
* Willing to undergo blood or fluid collection and tumour biopsy
* Patients enrolled at the time of surgery must agree to have part of their tumour used for the purpose of the study.
* Archival tissue must be available for patients that are enrolled at the time of progression.
Exclusion Criteria
* Must not have other tumour histology other than high grade serous.
* Must not have contraindication to tumour biopsy and/or blood sampling.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amit Oza, M.D.
Role: PRINCIPAL_INVESTIGATOR
Princess Margaret Cancer Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal Victoria Regional Health Centre
Barrie, Ontario, Canada
Juravinski Cancer Centre
Hamilton, Ontario, Canada
Kingston Health Sciences Centre
Kingston, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
The Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BioDIVA (17-5467)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.